The antibacterial and antifungal activities of gatifloxacin and its metal complexes

¹Muhammad Inam-Ul-Haq, ¹Tehseen Ahmed*, ²Fatima Ahmed

¹Department of Chemistry, University of Karachi, Karachi, Pakistan

²The First Faculty of Medicine of Charles University, Prague, Czech Republic

*Corresponding Author's Email: tahmed@uok.edu.pk

Abstract

The present article reports the biological activity of gatifloxacin separately and simultaneously as a ligand and in form of the metal complex *in vitro*. Gatifloxacin is a member of the fluoroquinolone group and members of this group form metal complexes due to their high tendency to bind with metal ions. The metal complexes of the gatifloxacin synthesized with several metals like Mg(II), Al(III), Ca(II), Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) in a ratio of 1:2 molar ratios of metal and ligand (M: L). It was observed that the fluorine group at position 6 and the piperazine group at position 7 greatly enhanced the spectrum of activity. Antibacterial and antifungal activities of gatifloxacin and its metal complexes were determined by the agar diffusion method. The biological activity (antibacterial and antifungal) was tested against *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Pseudomonas aeruginosa*, *Campylobacter jejuni*, *Neisseria gonorrhoeae*, *Corynebacterium diphtheriae*, *Clostridium perfringens*, *Pasteurella multocida*, and fungus *Aspergillus niger* and *Fusarium oxysporum*. It was concluded that the as-prepared gatifloxacin metal complexes with divalent and trivalent metal ions showed enhanced antibacterial activities while no antifungal activities in comparison to gatifloxacin were observed.

Keywords: Gatifloxacin; metals; antibacterial; antifungal activities

Highlight

- Synthesis of the metal complex,
- 1:2 ratios of metal and ligands
- Antibacterial and antifungal activities of gatifloxacin in form of metal complexes

1. Introduction

Gatifloxacin is a synthetic white crystalline chemotherapeutic agent, has a broad-spectrum antimicrobial activity and a unique mechanism of action. It is used as a racemate, with no net optical rotation. Gatifloxacin is a potent antibacterial agent belonging to the fluoroquinolone group. The antibacterial action of gatifloxacin results in inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of chromosomal DNA during bacterial cell division. The antibacterial activities of R and S enantiomers are virtually identical (Al-Abdullah, 2012). The maximum aqueous solubility (40-60 mg/mL) occurs at a pH range of 2-5 (Repchinsky, 2003). Gatifloxacin has a piperazino group at the C7 position. The methyl substituent on the piperazine ring enhances the Gram-positive activity, extends the half-life, and supports metabolic stability. It has a cyclopropyl group at the N1 position which enhances Gram-negative activity and contributes some Gram-positive activity. Gatifloxacin does not have a 2,4-difluorophenyl group at the N1 position which results in the lack of hepatic and hematologic toxicities associated with other fluoroquinolones (Blum et al., 1994; Lipsky, & Baker, 1999; Zhao et al., 1997). Due to the lack of halide at the C8 position, the photo-toxicity is reduced. The presence of the methoxy group at the C8 position enhances activity against DNA gyrase and topoisomerase IV. This substituent can reduce the potential for the development of bacterial resistance (Domagala, 1994; Park-Wyllie et al., 2006; Lipsky, & Baker, 1999; Drlica, 1999; Fukuda et al., 2001; Ito et al., 1995). Metal ions are known to affect the action of many drugs. The efficacy of the drugs on coordination with metal is enhanced in many cases (Farrell, 2003).

Metal ions play a vital role in a vast number of widely dissimilar biological processes and depending on their concentration, they might have either contributed towards the health of the organism or cause toxicity (Sabale et al., 2012; Sadler, & Guo, 1998). Several metals chelate are known to possess antibacterial, antifungal, antiviral, and anti-cancerous activity. In numerous cases, the metal chelates are more antimicrobial than the chelating agents themselves (Tarushi et al., 2013). The coordination chemistry of fluoroquinolone drugs with metal ions is of considerable interest associated with

biological and pharmaceutical significant metal. There have been several reports in the literature about the synthesis and crystal structure of metal complexes with different quinolone and fluoroquinolones group antibiotics.

The current research reports the synthesis of complex and their characterization using advanced technologies. The biological activities of synthesized complexes were measured *in vitro* study using the agar diffusion method.

2. Materials and methods

Gatifloxacin was obtained from Sigma-Aldrich. All reagents used were analytical and HPLC grade. Bi-distilled water was obtained by passing deionized water through a Millipore water system. This bi-distilled and deionized water was used in the preparation of all solutions of reagents and buffers. Gatifloxacin is a synthetic broad-spectrum quinolone antibacterial agent for ophthalmic uses. Chemically gatifloxacin is ($\pm$)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid sesquihydrate (Gayakwad et al., 2018). The empirical formula of gatifloxacin is $C_{19}H_{22}FN_3O_4 \cdot 1.5H_2O$ and its molecular weight is $402.42 \text{ g mol}^{-1}$ while the structural formula is shown in Figure 1.

Fig. 1. Chemical structure of gatifloxacin

2.1. Synthesis of the complexes

The metal complexes of gatifloxacin were prepared by using 50 mL of 1 mM hot methanolic solution of gatifloxacin with simultaneous addition of 50 mL of 0.5 mM solution of metal chloride ($MgCl_2 \cdot 6H_2O$, $AlCl_3 \cdot 6H_2O$, $CaCl_2 \cdot 2H_2O$, $CrCl_3 \cdot 6H_2O$, $MnCl_2 \cdot 4H_2O$, $FeCl_3 \cdot 6H_2O$, $CoCl_2 \cdot 6H_2O$, $NiCl_2 \cdot 6H_2O$, $CuCl_2 \cdot 2H_2O$, and $ZnCl_2$) in double-distilled water and mixing with a magnetic stirrer (chloride form of all metals chosen for complex preparation). In this preparation, a 1:2 molar ratio of metal and ligand (M: L) was used. The reaction mixture was continuously heated on a water bath for 4-4.5 h at $50^\circ C$, then the mixture was filtered and the solution concentrated under reduced pressure. The complexes were characterized by their elemental analysis, atomic absorption, infrared and UV-visible spectroscopy. Although gatifloxacin metal complexes are crystalline but not suitable for X-ray diffraction analysis. Characterization of metal complexes was conducted by physicochemical methods which are as follows while color of complexes monitored by visual observation

2.2. Solubility test

The solubility of the metal complexes was tested using a various polar solvent like methanol, DMF, and DMSO and non-polar solvents like benzene, cyclohexane, ether, and carbon tetrachloride

2.3. Melting point

The melting point of the metal complexes was recorded on a Gallenkamp melting point apparatus.

2.4. Analysis of the synthesized complexes

The IR spectra of gatifloxacin and their metal complexes were recorded on a Shimadzu FTIR Prestige -21 spectrophotometer by using KBr pellets in the $4000-400 \text{ cm}^{-1}$ range. The elemental analysis was carried out with a standard micro method using Carlo-Erba 1106. Perkin-Elmer Analyst 700 atomic absorption spectrometers used for atomic absorption studies. The

UV-visible spectra were recorded on Beckman Coulter DU 730 and Shimadzu 1700 connected to computer loaded UV-Probe version 2.3 software. HPLC studies were carried out on Lab Alliance HPLC connected with NavChrom software and the Shimadzu Technologies LC 20 series LC system was used for method development and validation studies. The chromatograms were analyzed with Shimadzu lab solution HPLC software.

2.5. Biological Activities

In vitro antibacterial and antifungal activities of gatifloxacin and its metal complexes were determined by agar diffusion method (Perilla, 2003; FDA, 2015) against different bacterial strains such as *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Pseudomonas aeruginosa*, *Campylobacter jejuni*, *Neisseria gonorrhoeae*, *Corynebacterium diphtheriae*, *Clostridium perfringens*, *Pasteurella multocida*, and fungus *Aspergillus niger* and *Fusarium oxysporum*. For this purpose, different concentrations (5, 10, 20, and 40 µg/mL) of antibacterial discs (6 mm) were prepared and dried at 37 °C. The nutrient agar medium (Oxoid) was used for antibacterial and for antifungal studies, the sabouraud dextrose agar medium (Merck) was prepared, then cooled to 40 °C and seeded with test microorganisms. These culture plates were then incubated at 37 °C for 24 h for bacteria while seven days at 30 °C for fungal culture. The activity was determined by measuring the diameter of the inhibition zone (in mm). Growth inhibition was calculated regarding the positive control of gatifloxacin. While DMSO paper discs were used as a negative control to assess the positive control (Table 1).

TABLE 1

Antibacterial and antifungal activity of gatifloxacin and Its metal complexes

[illegible]

Abbreviation: *C. perfringens* *Clostridium perfringens*, *C. jejuni* *Campylobacter jejuni*, *C. diphtheriae* *Corynebacterium diphtheriae*, *E. coli* *Escherichia coli*, *S. aureus* *Staphylococcus aureus*, *S. typhi* *Salmonella typhi*, *P. aeruginosa* *Pseudomonas aeruginosa*, *P. multocida* *Pasteurella multocida*, *N. gonorrhoeae* *Neisseria gonorrhoeae*, *A. niger* *Aspergillus niger* and *F. oxysporum* *Fusarium oxysporum*

Excellent activity	= +++++	(150-200% inhibition)
Good activity	= ++++	(90-100% inhibition)
Moderate activity	= +++	(75-85% inhibition)
Significant activity	= ++	(50-60% inhibition)
Negligible activity	= +	(20-30% inhibition)
No activity	=	(n.a)

3. Results and Discussion

3.1. Stoichiometry of Gatifloxacin-Metal Complexes

Stoichiometry of gatifloxacin-metal complexes was studied by mole ratio and Job's methods. These methods are excellent when M and L species have different spectroscopic properties as compared to the complex ML_n . Initially, $\lambda_{\max}$ was calculated by scanning the spectrum of gatifloxacin-metal complexes at pH under consideration. During the scanning of the spectrum, it was found that the $\lambda_{\max}$ value of gatifloxacin-metal complexes varied with pH.

3.2. Synthesis and characterization

3.2.1. Physicochemical properties of the Gatifloxacin metal complexes

The metal complexes were prepared by refluxing in an appropriate amount of metal salts with gatifloxacin in methanol. Metal complexes were prepared by using the metal salts of chloride ion with the gatifloxacin in molar ratios of metal to the ligand in the ratio 1:2. It was observed that the data of calculated percentages of elemental analysis (CHN) were in good agreement with each other and proved the suggested molecular formulas of the complexes (Table 2 & Fig. 2).

Table 2

Physicochemical parameters of gatifloxacin and its metal complexes

S.No	Compound	Color	M.P. °C	%Yield
1	Gatifloxacin	Off White	158	-----
2	$[Mg(C_{19}H_{22}N_3O_4F)_2(H_2O)_2] Cl_2 \cdot 2H_2O$	Off White	250	81
3	$[Al(C_{19}H_{22}N_3O_4F)_2Cl(H_2O)]Cl \cdot 2H_2O$	Off White	197	82
4	$[Ca(C_{19}H_{22}N_3O_4F)_2(H_2O)_2] Cl_2 \cdot 2H_2O$	Off White	227	83
5	$[Cr(C_{19}H_{22}N_3O_4F)_2Cl(H_2O)_2] Cl \cdot 2H_2O$	Green	222	82
6	$[Mn(C_{19}H_{22}N_3O_4F)_2(H_2O)_2] \cdot 6H_2O$	Pale yellow	221	84
7	$[Fe(C_{19}H_{22}N_3O_4F)_2Cl(H_2O)_2] Cl \cdot 2H_2O$	Reddish brown	191	87
8	$[Co(C_{19}H_{22}N_3O_4F)_2(H_2O)_2] \cdot 4H_2O$	Pink	193	87

9	[Ni (C ₁₉ H ₂₂ N ₃ O ₄ F) ₂ (H ₂ O) ₂] Cl ₂ ·2H ₂ O	Light green	258	90
10	[Cu (C ₁₉ H ₂₂ N ₃ O ₄ F) ₂ (H ₂ O) ₂]·H ₂ O	Dirty green	175	87
11	[Zn (C ₁₉ H ₂₂ N ₃ O ₄ F) ₂ (H ₂ O) ₂]·2H ₂ O	Dirty White	191	78

Fig. 2. Proposed structural formula of metal complex

3.2.2. Solubility and Melting point

The solubility test of these complexes showed that they were insoluble in benzene, cyclohexane, ether, and carbon tetrachloride while slightly soluble in water while soluble in methanol, DMF, and DMSO. The melting point obtained for each of these complexes is found to be higher than the melting point of the ligand. This shows that there is coordination between the ligand and their metal salts, thereby resulting in complexation (Table 2).

3.3. Elemental Analysis of the complexes

Atomic absorption analysis was carried out by direct method to estimate the total metal contents. For this purpose, the reference solutions of different metals having various concentrations were prepared. The absorbance was noted at a specific wavelength of each metal by using the background correction technique (Farrell, 2003). For each metal solution, the graph was plotted between absorbance and concentration. The concentration of the unknown solution was calculated from the absorbance of the unknown solution using standard values. The results obtained from elemental analysis and atomic absorption are shown in Table 3. These results suggest the same formulas of the gatifloxacin metal complexes is [M(gati)₂·nH₂O] Cl₂·nH₂O. The most probable structures of the complexes are shown in Fig. 3. The gatifloxacin complexes most probably have six coordinates with two molecules of gatifloxacin chelating metal atom and four other atoms derived from water and chloride ions.

TABLE 3

Elemental analysis of gatifloxacin and its metal complexes

S.N	Compound	C%	H%	N%	Metal %
1	Gatifloxacin	56.71	6.21	10.44	-----
2	[Mg(C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂] Cl ₂ ·2H ₂ O	50.02, (49.71)	5.49, (5.66)	9.14, (9.15)	2.72, (2.64)
3	[Al(C ₁₉ H ₂₂ FN ₃ O ₄) ₂ ClH ₂ O]Cl ₂ ·2H ₂ O	50.01, (50.55)	5.21, (5.54)	9.10, (9.31)	2.81, (2.99)
4	[Ca(C ₁₉ H ₂₂ FN ₃ O ₄) ₂ (H ₂ O) ₂] Cl ₂ ·2H ₂ O	48.52, (48.87)	5.40, (5.57)	9.01, (9.00)	4.32, (4.29)
5	[Cr(C ₁₉ H ₂₂ FN ₃ O ₄) ₂ Cl(H ₂ O) ₂] Cl ₂ ·2H ₂ O	48.15, (48.25)	5.15, (5.50)	9.01, (8.88)	5.48, (5.50)

6	[Mn (C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂]-6H ₂ O	48.00, (48.05)	6.11, (6.32)	8.84, (8.85)	5.74, (5.79)
7	[Fe(C ₁₉ H ₂₂ F N ₃ O ₄) ₂ Cl(H ₂ O) ₂] Cl ₂ ·2H ₂ O	48.65, (48.05)	5.48, (5.48)	8.82, (8.85)	5.84, (5.90)
8	[Co (C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂]-4H ₂ O	50.02, (49.73)	5.89, (6.10)	9.12, (9.16)	6.41, (6.43)
9	[Ni (C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂] Cl ₂ ·2H ₂ O	48.00, (47.91)	5.28, (5.46)	8.85, (8.82)	6.01, (6.16)
10	[Cu (C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂]-H ₂ O	51.81, (52.56)	5.67, (5.76)	9.56, (9.68)	7.01, (7.32)
11	[Zn (C ₁₉ H ₂₂ F N ₃ O ₄) ₂ (H ₂ O) ₂]-H ₂ O	51.23, (51.38)	5.58, (5.85)	9.34, (9.46)	7.35, (7.36)

Fig. 3. Spectrum of gatifloxacin complexes

3.4. UV-Visible Analysis of the metal complexes

The characterization of synthesized metal complexes was also conducted by UV-visible spectrophotometry. The spectra of the gatifloxacin and its metal complexes were scanned in the region of 200 – 800 nm. The spectral analysis of all metal complexes showed absorption maxima around 330 nm which may be assigned to ligand-metal electron transfer. The absorption spectrum of gatifloxacin showed three absorption peaks at 254, 291 and 310 nm, these peaks could be assigned to $\pi - \pi^*$ and $n - \pi^*$ transition within the organic ligand (Saravolatz, & Leggett, 2003). In all gatifloxacin complexes the maximum absorption peaks had relatively high bathochromic shifts, this can be attributed to the reaction of the metal ions with the ketonic oxygen and carboxylic oxygen in the conjugated system of the drug, which directly resulted in the changes of absorption spectra and bathochromic shifts of the maximum absorption peaks. Whereas in the case of gatifloxacin complexes new absorption peaks appeared around 330 nm and all the other absorption peaks are bathochromic shifted. The shift of λ_{max} to higher values (bathochromic shift) and lower values (hypsochromic shift) for the complexes attributed to the complexation behavior of gatifloxacin towards metal ions (Fig.3 &4).

Fig.4. Proposed structural formula of Co(II) gatifloxacin complex

3.5. Infrared analysis of the metal complexes

The infrared (IR) spectral scanning of gatifloxacin sesquihydrate, anhydrous gatifloxacin, and the synthetic complexes were conducted for the validation of complexes. The IR spectra of gatifloxacin sesquihydrate were scanned against the reference standard to identify during stability studies. The values of different functional groups in IR spectra of anhydrous gatifloxacin and their metal complexes were reported in Table 4.

TABLE 4

FTIR absorption data of gatifloxacin and its metal complexes (4000-400 Cm^{-1})

Assignments(cm^{-1})	GT	GTX Complex with									
GTX and GTX-Complex	X	Mg	Ca	Al	Cr	Mn	Fe	Co	Ni	Cu	Zn
	340				344	342					
$\nu(\text{OH})$ intermol	0	3415	3412	3456	6	5	3451	3396	3396	3409	3415
	310				293	308					
$\nu(\text{CH})$ arom	0	2983	3072	3025	9	8	3025	2990	2999	3000	2980
	284				285	284					
$\nu(\text{CH})$ aliph	3	2845	2842	2842	2	7	2856	2843	2842	2834	2844
	237				249	249					
$\nu(\text{NH})$ and (OH) chel	5	2491	2480	2361	1	1	2480	2480	2480	2470	2491
	163				161	161					
$\nu(\text{COO}-)$ as	8	1619	1616	1618	8	5	1623	1608	1621	1619	1620
	139				139	139					
$\nu(\text{COO}-)$ sym	8	1407	1400	1404	8	9	1396	1399	1369	1374	1398
$\Delta\nu=(\text{COO}-)$ as- $\nu(\text{COO}-)$ sym	240	212	216	214	220	214	227	209	252	245	222
	144				144	144					
$\nu(\text{C}=\text{C}$ and $\text{C}-\text{N})$	8	1460	1451	1458	8	9	1442	1448	1459	1448	1448
				1569				1571	1577	1562	1574
		1582,		,	151	157		,	,	,	,
$\nu(\text{COOM})$		1530	1580	1524	5	0	1515	1523	1520	1515	1531
	136				137	136					
$\nu(\text{C}-\text{N})$	6	1370	1370	1357	5	7	1364	1367	1371	1376	1370
	107				106	106					
$\nu(\text{C}-\text{F}, \text{C}-\text{O})$	2	1072	1060	1055	7	0	1060	1060	1061	1055	1061
		651,551,5	650,549,5				658,55	651,	550,		
$\nu(\text{M}-\text{O})$		19	19	651	532	654	8	550	495	657	653

The IR spectra of gatifloxacin metal complexes were compared with that of anhydrous gatifloxacin for the determination of the coordination sites involved in complex formation. The valence vibration of the carboxylic stretch $\nu(\text{C}=\text{O})_{\text{c}}$ was found at 1726 cm^{-1} and the pyridone stretch $\nu(\text{C}=\text{O})_{\text{p}}$ at 1618 cm^{-1} . The IR spectrum of gatifloxacin sesquihydrate does not show a well-defined carboxylic stretch, which is consistent with the deprotonation of the carboxylic acid. The molecule exists in bipolar zwitterionic form. Ionic carboxylates show no carbonyl stretch of approximately 1700 cm^{-1} , but the two bands in the range from 1650 to 1510 cm^{-1} and from 1460 to 1400 cm^{-1} , could be assigned to $(\text{O}-\text{C}-\text{O})$ asymmetric and symmetric stretching vibrations. In the spectrum of gatifloxacin sesquihydrate the $(\text{O}-\text{C}-\text{O})_{\text{a}} + (\text{C}=\text{O})_{\text{p}}$ band appears at $1600\text{--}1658 \text{ cm}^{-1}$ with a maximum at 1638 cm^{-1} , $(\text{O}-\text{C}-\text{O})_{\text{s}}$ band stretch is at 1398 cm^{-1} and $\text{C}-\text{O}$ absorbs at 1282 cm^{-1} . It was found that on complexation, the characteristic peak of $(\text{C}=\text{O})_{\text{p}} + (\text{C}-\text{O}-\text{C})_{\text{a}}$ in spectra of all-metal complexes shifted

towards lower frequency region i-e in the range 1608–1623 cm^{-1} and the symmetric vibrations occur in the region of 1407–1370 cm^{-1} (Ambrose, & Grasela 1999; Grasela, 2000; Patrick, 2013). These complexes show strong intensity absorption in the region of 1540–1500 cm^{-1} and weak bands in the region of 651–532 cm^{-1} and 450–400 cm^{-1} , which are absent in the spectrum of gatifloxacin. All gatifloxacin metal complexes show a broad band between 3590 and 3147 cm^{-1} with a maximum around 3410 cm^{-1} , corresponding to vibrations m(O-H) as well as vibration N-H piperazinyl fraction (Grasela, 2000). The latter signal appears in the region of 2491 - 2344 cm^{-1} in the IR spectra of the complexes. It indicates that the carboxyl group is deprotonated and the bipolar molecule exists with hydrogen atoms bonded to N-3 to form bonds with hydrogen donors water molecules.

The biological activity of the gatifloxacin and its metal complexes was assayed against the adversity of bacterial strains such as *Clostridium perfringens*, *Campylobacter jejuni*, *Corynebacterium diphtheriae*, *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Pseudomonas aeruginosa*, *Pasteurella multocida*, and *Neisseria gonorrhoeae*. The antifungal screening involved two fungus species *Aspergillus niger* and *Fusarium oxysporum*. The results of the antibacterial study of the synthesized compounds are shown in Table 1. The results were expressed as excellent activity (150–200% inhibition), good activity (90–100% inhibition), moderate activity (75–85% inhibition), significant activity (50–60% inhibition), negligible activity (20–30% inhibition) and no activity.

GTX-Al exhibits good activity whereas all metal complexes show excellent activity against *C. perfringens*. GTX-Mg, GTX-Co, GTX-Zn show good activity while GTX-Fe, GTX-Ni, and GTX-Cu show excellent activity, and GTX-Ca, GTX-Al, GTX-Cr, GTX-Mn has moderate activity against *C. jejuni*. GTX-Al has moderate activity and the remaining complexes show excellent activity against *C. diphtheriae*. Diverse activity against Gram-negative organisms was observed. GTX-Ca and GTX-Mn show excellent activity while GTX-Al exhibits moderate activity. The remaining complexes reflect activity, similar to the gatifloxacin against *E. coli*. The result GTX-Mg, GTX-Ni, and GTX-Zn show surprisingly excellent activity against *S. aureus* (methicillin-resistant) while GTX-Al has moderate activity and the remaining complexes show activity that is similar to gatifloxacin. Against *S. typhi* GTX-Ca, GTX-Al, GTX-Mn, GTX-Ni, and GTX-Cu exhibits moderate activity while GTX-Mg and GTX-Fe show excellent activity, and GTX-Cr, GTX-Co, GTX-Zn show similar activity to gatifloxacin. GTX-Ca, GTX-Mn, and GTX-Co show excellent antibacterial activity whereas GTX-Al, GTX-Cr, and GTX-Cu show moderate and other complexes show similar activity to gatifloxacin against *P. aeruginosa*. Except for GTX-Ca and GTX-Al, all complexes have excellent intrinsic activity against bacterium *P. multocida*. GTX-Mg shows excellent activity whereas the rest of the complexes exhibit similar activity to that of gatifloxacin against *N. gonorrhoeae*. The enhanced intrinsic activity of complexes can be explained based on cell permeability. The lipid membrane around the cell favors the penetration of lipid-soluble materials. Liposolubility is a key factor that controls antimicrobial activity. Increased liposolubility of the ligand upon metal chelation may contribute to its facilitated transport into the bacterial cell, which blocks the metal-binding sites in the enzymes of microorganisms (Tümer et al., 1999; Imran et al., 2007; Sultana et al., 2013; Jain et al., 2002).

4. Conclusion

Antimicrobial analysis of the complexes and ligand were evaluated among different bacterial strains such as *Clostridium perfringens* (*C. perfringens*), *Campylobacter jejuni* (*C. jejuni*), *Corynebacterium diphtheriae* (*C. diphtheriae*), *Escherichia coli* (*E. coli*), *Staphylococcus aureus* (*S. aureus*), *Salmonella typhi* (*S. typhi*), *Pseudomonas aeruginosa* (*P. aeruginosa*), *Pasteurella multocida* (*P. multocida*), *Neisseria gonorrhoeae* (*N. gonorrhoeae*) and fungal strains were studied against two species fungus *Aspergillus niger* (*A. niger*) and *Fusarium oxysporum* (*F. oxysporum*). The present study concluded that gatifloxacin and metal complexes can be used as a good drug of choice to manage bacterial diseases after evaluating the *in-vitro* studies. The antibacterial activity of the metal complexes of gatifloxacin was found to highly active as compared to gatifloxacin itself. It was also observed that pH affected the antibacterial activity of metal complexes.

Conflict of interest

It is declared that there is no conflict of interest in between Authors

Acknowledgment

The Authors are grateful to Dean faculty of Science for provide funds to execute this project.

References

1. Al-Abdullah, E. S. (2012). Gatifloxacin. In Profiles of Drug Substances, Excipients and Related Methodology (Vol. 37, pp. 183-243). Academic Press.
2. Repchinsky, C. (2003). CPS 2003. Canadian Pharmacists Association. Ottawa, Ontario.
3. Blum, M. D., Graham, D. J., & McCloskey, C. A. (1994). Temafloxacin syndrome: review of 95 cases. *Clinical Infectious Diseases*, 18(6), 946-950.
4. Lipsky, B. A., & Baker, C. A. (1999). Fluoroquinolone toxicity profiles: a review focusing on newer agents. *Clinical Infectious Diseases*, 28(2), 352-361.
5. Zhao, X., Xu, C., Domagala, J., & Drlica, K. (1997). DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. *Proceedings of the National Academy of Sciences*, 94(25), 13991-13996.
6. Domagala, J. M. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials. *Journal of Antimicrobial Chemotherapy*, 33(4), 685-706.
7. Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., ... & Mamdani, M. M. (2006). Outpatient gatifloxacin therapy and dysglycemia in older adults. *New England Journal of Medicine*, 354(13), 1352-1361.
8. Drlica, K. (1999). Features-Refining the Fluoroquinolones-Basic efforts to understand quinolone biology may prolong the health value of these widely used antibacterial agents. *ASM News-American Society for Microbiology*, 65(6), 410-415.
9. Fukuda, H., Kishii, R., Takei, M., & Hosaka, M. (2001). Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against *Streptococcus pneumoniae*. *Antimicrobial agents and chemotherapy*, 45(6), 1649-1653.
10. Ito, T., Matsumoto, M., & Nishino, T. (1995). Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. *Antimicrobial agents and chemotherapy*, 39(7), 1522-1525.
11. Fukuda, H., & Hiramatsu, K. (1999). Primary Targets of Fluoroquinolones in *Streptococcus pneumoniae*. *Antimicrobial Agents and Chemotherapy*, 43(2), 410-412.
12. Farrell, N. (2003). Metal complexes as drugs and chemotherapeutic agents. 809-840.
13. Sabale, P. M., Kaur, P., Patel, Y., Patel, J., & Patel, R. (2012). Metalloantibiotics in therapy: An overview. *J Chem Pharm Res*, 4(11), 4921-4936.
14. Sadler, P. J., & Guo, Z. (1998). Metal complexes in medicine: design and mechanism of action. *Pure and Applied Chemistry*, 70(4), 863-871.
15. Tarushi, A., Kljun, J., Turel, I., Pantazaki, A. A., Psomas, G., & Kessissoglou, D. P. (2013). Zinc (II) complexes with the quinolone antibacterial drug flumequine: structure, DNA-and albumin-binding. *New Journal of Chemistry*, 37(2), 342-355.
16. Perilla, M. J. (2003). Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health importance in the developing world; *Haemophilus influenzae*, *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Neisseria gonorrhoeae*, *Salmonella* serotype Typhi, *Shigella*, and *Vibrio cholerae*.
17. FDA, A. P. (2015). Methods Validation for Drugs and Biologics Guidance for Industry, US Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
18. Tümer, M., Köksal, H., Sener, M. K., & Serin, S. (1999). Antimicrobial activity studies of the binuclear metal complexes derived from tridentate Schiff base ligands. *Transition Metal Chemistry*, 24(4), 414-420.
19. Imran, M., Iqbal, J., Iqbal, S., & Ijaz, N. (2007). In vitro antibacterial studies of ciprofloxacin-imines and their complexes with Cu (II), Ni (II), Co (II), and Zn (II). *Turkish journal of biology*, 31(2), 67-72.
20. Sultana, N., Arayne, M. S., Rizvi, S. B. S., Haroon, U., & Mesaik, M. A. (2013). Synthesis, spectroscopic, and biological evaluation of some levofloxacin metal complexes. *Medicinal Chemistry Research*, 22(3), 1371-1377.
21. Jain, S., Jain, N. K., & Pitre, K. S. (2002). Bio-inorganic studies on the Fe (II) sparfloxacin complex. *Metal-Based Drugs*, 9(1-2), 1-8.
22. Saravolatz, L. D., & Leggett, J. (2003). Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. *Clinical infectious diseases*, 37(9), 1210-1215.

23. Grasela, D. M. (2000). Clinical pharmacology of gatifloxacin, a new fluoroquinolone. *Clinical infectious diseases*, 31(Supplement_2), S51-S58.
24. Ambrose, P. G., & Grasela, D. M. (1999, September). Effect of pharmacokinetic and microbiological variability on the pharmacodynamics of gatifloxacin and levofloxacin against *Streptococcus pneumoniae*. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.
25. Patrick, G. L. (2013). *An introduction to medicinal chemistry*. Oxford university press.

Received: 17th August, 2020

Accepted: 21th November, 2020